Role of genotyping in non-small cell lung cancer treatment: Current status

Drugs

Volumn 71, Issue 17, 2011, Pages 2231-2246

  Bonanno, Laura ^a   Favaretto, Adolfo ^a   Rugge, Massimo ^b,c   Taron, Miquel ^d,e   Rosell, Rafael ^d,e  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d INSTITUT UNIVERSITARI DEXEUS   (Spain)

^e HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Afatinib; Cisplatin; Crizotinib; Dacomitinib; Dasatinib; Erlotinib; GDC 0980; Gefitinib; Non small cell lung cancer; PD 173074

Indexed keywords

1 TERT BUTYL 3 [6 (3,5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO)PYRIDO[2,3 D]PYRIMIDIN 7 YL]UREA; ADENYLATE KINASE; AFATINIB; ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; B RAF KINASE; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CRIZOTINIB; DACOMITINIB; DASATINIB; DISCOIDIN DOMAIN RECEPTOR 2; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GDC 0980; GEFITINIB; GEMCITABINE; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PEMETREXED; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PROTEIN SERINE THREONINE KINASE; RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CANCER CHEMOTHERAPY; CANCER SURVIVAL; DRUG EFFICACY; DRUG TARGETING; DRUG TOLERABILITY; EXCISION REPAIR; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; GENE REARRANGEMENT; GENOTYPE; HETEROZYGOSITY LOSS; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MUTATIONAL ANALYSIS; ONCOGENE K RAS; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGNOSIS; PROGRESSION FREE SURVIVAL; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE;

CARCINOMA, NON-SMALL-CELL LUNG; GENOTYPE; GENOTYPING TECHNIQUES; HUMANS; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS;

EID: 81155123620     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11597700-000000000-00000     Document Type: Review

References (135)

1. Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007 Aug; 2 (8): 706-14 (Pubitemid 47357522)
2. Pao W, Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 2010 Nov; 10 (11): 760-74
3. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-smallcell lung cancer. N Engl J Med 2002 Jan 10; 346 (2): 92-8 (Pubitemid 34438899)
4. Travis WD, Brambilla E, Mü ller-Hermelink HK, et al. WHO histological classification of tumours of the lung. In: Travis WD, Brambilla E, Mü ller-Hermelink HK, et al. World Health Organization classification of tumours: pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon: IARC Press, 2004: 10-11
5. Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011 Feb; 6 (2): 244-85
6. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006 Dec 14; 355 (24): 2542-50 (Pubitemid 44917502)
7. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous nonsmall-cell lung cancer: AVAil. J Clin Oncol 2009 Mar 10; 27 (8): 1227-34
8. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advancedstage non-small-cell lung cancer. J Clin Oncol 2008 Jul 20; 26 (21): 3543-51
9. Gronberg BH, Bremnes RM, Flotten O, et al. Phase III study by theNorwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2009 Jul 1; 27 (19): 3217-24
10. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004 May 1; 22 (9): 1589-97 (Pubitemid 41079796)
11. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009 Oct 24; 374 (9699): 1432-40
12. Scagliotti GV, Selvaggi G. New data integrating multitargeted antifolates into treatment of first-line and relapsed non-small-cell lung cancer. Clin Lung Cancer 2008; 9 Suppl. 3: S122-8
13. Crino L, Dansin E, Garrido P, et al. Safety and efficacy of first-line bevacizumab-based therapy in advanced nonsquamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol 2010 Aug; 11 (8): 733-40
14. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004 Jun 1; 22 (11): 2184-91 (Pubitemid 41095154)
15. Weinstein IB. Cancer: addiction to oncogenes. The Achilles heal of cancer. Science 2002 Jul 5; 297 (5578): 63-4 (Pubitemid 34743088)
16. Weinstein IB, Joe AK. Mechanisms of disease: oncogene addiction. A rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol 2006 Aug; 3 (8): 448-57 (Pubitemid 44203817)
17. Ding L, Getz G, Wheeler DA, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008 Oct 23; 455 (7216): 1069-75
18. Sharma SV, Haber DA, Settleman J. Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat Rev Cancer 2010 Apr; 10 (4): 241-53
19. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004 Jun 4; 304 (5676): 1497-500 (Pubitemid 38720929)
20. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004 May 20; 350 (21): 2129-39 (Pubitemid 38637993)
21. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004 Sep 7; 101 (36): 13306-11 (Pubitemid 39209661)
22. Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009 Sep 3; 361 (10): 958-67
23. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009 Sep 3; 361 (10): 947-57
24. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010 Feb; 11 (2): 121-8
25. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010 Jun 24; 362 (25): 2380-8
26. Engelman JA, Zejnullahu K, Gale CM, et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 2007 Dec 15; 67 (24): 11924-32
27. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011 Aug; 12 (8): 735-42
28. Rosell R, Gervais R, Vergnenegre A, et al. Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial [abstract no. 7503]. J Clin Oncol 2011; 29 Suppl.
29. D'Addario G, Fruh M, Reck M, et al. Metastatic nonsmall-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010 May; 21 Suppl. 5: v116-9
30. Ettinger SE, Akerley W, Borghaei H, et al. NCCN clinical practice guidelines in oncology: non-small cell lung cancer. NCCN clinical practice guidelines in Oncology 2011 [online]. Available from URL: http://www.nccn.org/ pro fessionals/physician-gls/f-guidelines.asp [Accessed 2011 Oct 26]
31. Azzoli CG, Baker Jr S, Temin S, et al. American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009 Dec 20; 27 (36): 6251-66
32. Miyamae Y, Shimizu K, Hirato J, et al. Significance of epidermal growth factor receptor gene mutations in squamous cell lung carcinoma. Oncol Rep 2011 Apr; 25 (4): 921-8
33. Kang SM, Kang HJ, Shin JH, et al. Identical epidermal growth factor receptor mutations in adenocarcinomatous and squamous cell carcinomatous components of adenosquamous carcinoma of the lung. Cancer 2007 Feb 1; 109 (3): 581-7 (Pubitemid 46190967)
34. Toyooka S, Yatabe Y, Tokumo M, et al. Mutations of epidermal growth factor receptor and K-ras genes in adenosquamous carcinoma of the lung. Int J Cancer 2006 Mar 15; 118 (6): 1588-90
35. Jackman D, Pao W, Riely GJ, et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol 2010 Jan 10; 28 (2): 357-60
36. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005 Feb 24; 352 (8): 786-92 (Pubitemid 40271173)
37. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005 Mar; 2 (3): e73
38. Balak MN, Gong Y, Riely GJ, et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 2006 Nov 1; 12 (21): 6494-501 (Pubitemid 44799723)
39. Yun CH, Mengwasser KE, Toms AV, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 2008 Feb 12; 105 (6): 2070-5 (Pubitemid 351439466)
40. Kuang Y, Rogers A, Yeap BY, et al. Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant nonsmall cell lung cancer. Clin Cancer Res 2009 Apr 15; 15 (8): 2630-6
41. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007 May 18; 316 (5827): 1039-43 (Pubitemid 46799492)
42. Bean J, Brennan C, Shih JY, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007 Dec 26; 104 (52): 20932-7
43. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011 Mar 23; 3 (75): 75ra26
44. Kwak EL, Sordella R, Bell DW, et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA 2005 May 24; 102 (21): 7665-70 (Pubitemid 40741028)
45. Carter TA, Wodicka LM, Shah NP, et al. Inhibition of drug-resistant mutants of A BL, K IT, and EGF receptor kinases. Proc Natl Acad Sci USA 2005 Aug 2; 102 (31): 11011-6 (Pubitemid 41105984)
46. Bean J, Riely GJ, Balak M, et al. Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. Clin Cancer Res 2008 Nov 15; 14 (22): 7519-25
47. Li D, Ambrogio L, Shimamura T, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008 Aug 7; 27 (34): 4702-11
48. Godin-Heymann N, Ulkus L, Brannigan BW, et al. The T790M 'gatekeeper' mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor. Mol Cancer Ther 2008 Apr; 7 (4): 874-9 (Pubitemid 351551040)
49. Sos ML, Rode HB, Heynck S, et al. Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation. Cancer Res 2010 Feb 1; 70 (3): 868-74
50. Maheswaran S, Sequist LV, Nagrath S, et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008 Jul 24; 359 (4): 366-77
51. Rosell R, Molina MA, Costa C, et al. Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. Clin Cancer Res 2011 Mar 1; 17 (5): 1160-8
52. Bivona TG, Hieronymus H, Parker J, et al. FAS and NFkappaB signalling modulate dependence of lung cancers on mutant EGFR. Nature 2011 Mar 24; 471 (7339): 523-6
53. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007 Aug 2; 448 (7153): 561-6 (Pubitemid 47206930)
54. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010 Oct 28; 363 (18): 1693-703
55. Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, A LK, to a nucleolar protein gene, N PM, in non-Hodgkin's lymphoma. Science 1994 Mar 4; 263 (5151): 1281-4 (Pubitemid 24107549)
56. Choi YL, Takeuchi K, Soda M, et al. Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res 2008 Jul 1; 68 (13): 4971-6
57. Takeuchi K, Choi YL, Togashi Y, et al.KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistrybased diagnostic system for ALK-positive lung cancer. Clin Cancer Res 2009 May 1; 15 (9): 3143-9
58. Koivunen JP, Mermel C, Zejnullahu K, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 2008 Jul 1; 14 (13): 4275-83
59. Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007 Dec 14; 131 (6): 1190-203 (Pubitemid 350235027)
60. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009 Sep 10; 27 (26): 4247-53
61. Rodig SJ, Mino-Kenudson M, Dacic S, et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 2009 Aug 15; 15 (16): 5216-23
62. Shaw AT, Solomon B. Targeting anaplastic lymphoma kinase in lung cancer. Clin Cancer Res 2011 Apr 15; 17 (8): 2081-6
63. Choi YL, Soda M, Yamashita Y, et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010 Oct 28; 363 (18): 1734-9
64. Camidge DR, Kono SA, Flacco A, et al. Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res 2010 Nov 15; 16 (22): 5581-90
65. Yi ES, Boland JM, Maleszewski JJ, et al. Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH. J Thorac Oncol 2011 Mar; 6 (3): 459-65
66. Shigematsu H, Takahashi T, Nomura M, et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res 2005 Mar 1; 65 (5): 1642-6 (Pubitemid 40478587)
67. Liu L, Shao X, Gao W, et al. The role of human epidermal growth factor receptor 2 as a prognostic factor in lung cancer: a meta-analysis of published data. J Thorac Oncol 2010 Dec; 5 (12): 1922-32
68. Gatzemeier U, Groth G, Butts C, et al. Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann Oncol 2004 Jan; 15 (1): 19-27 (Pubitemid 38139598)
69. Riely GJ, Marks J, Pao W. KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc 2009 Apr 15; 6 (2): 201-5
70. Riely GJ, Kris MG, Rosenbaum D, et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res 2008 Sep 15; 14 (18): 5731-4
71. Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005 Jan; 2 (1): e17
72. Mao C, Qiu LX, Liao RY, et al. KRAS mutations and resistance to EGFR-TKIs treatment in patients with nonsmall cell lung cancer: a meta-analysis of 22 studies. Lung Cancer 2010 Sep; 69 (3): 272-8
73. Mascaux C, Iannino N, Martin B, et al. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 2005 Jan 17; 92 (1): 131-9 (Pubitemid 40188446)
74. Garassino MC, Marabese M, Rusconi P, et al. Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer. Ann Oncol 2011 Jan; 22 (1): 235-7
75. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002 Jun 27; 417 (6892): 949-54 (Pubitemid 34716871)
76. Naoki K, Chen TH, Richards WG, et al. Missense mutations of the BRAF gene in human lung adenocarcinoma. Cancer Res 2002 Dec 1; 62 (23): 7001-3 (Pubitemid 35424093)
77. Pratilas CA, Hanrahan AJ, Halilovic E, et al. Genetic predictors of MEK dependence in non-small cell lung cancer. Cancer Res 2008 Nov 15; 68 (22): 9375-83
78. Sanchez-Cespedes M, Parrella P, Esteller M, et al. Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res 2002 Jul 1; 62 (13): 3659-62 (Pubitemid 34728843)
79. Ji H, Ramsey MR, Hayes DN, et al. LKB1 modulates lung cancer differentiation and metastasis. Nature 2007 Aug 16; 448 (7155): 807-10 (Pubitemid 47266337)
80. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 2008 Sep 25; 359 (13): 1367-80
81. Sobottka SB, Haase M, Fitze G, et al. Frequent loss of heterozygosity at the 19p13.3 locus without LKB1/STK11 mutations in human carcinoma metastases to the brain. J Neurooncol 2000 Sep; 49 (3): 187-95 (Pubitemid 32106780)
82. Mahoney CL, Choudhury B, Davies H, et al. LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition. Br J Cancer 2009 Jan 27; 100 (2): 370-5
83. Weir BA, Woo MS, Getz G, et al. Characterizing the cancer genome in lung adenocarcinoma. Nature 2007 Dec 6; 450 (7171): 893-8 (Pubitemid 350231325)
84. Yamamoto H, Shigematsu H, Nomura M, et al. PIK3CA mutations and copy number gains in human lung cancers. Cancer Res 2008 Sep 1; 68 (17): 6913-21
85. Kawano O, Sasaki H, Okuda K, et al. PIK3CA gene amplification in Japanese non-small cell lung cancer. Lung Cancer 2007 Oct; 58 (1): 159-60 (Pubitemid 47379973)
86. Angulo B, Suarez-Gauthier A, Lopez-Rios F, et al. Expression signatures in lung cancer reveal a profile for EGFR-mutant tumours and identify selective PIK3CA overexpression by gene amplification. J Pathol 2008 Feb; 214 (3): 347-56 (Pubitemid 351212390)
87. Weiss J, Sos ML, Seidel D, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2010 Dec 15; 2 (62): 62ra93
88. Qian J, Massion PP. Role of chromosome 3q amplification in lung cancer. J Thorac Oncol 2008 Mar; 3 (3): 212-5 (Pubitemid 351654319)
89. Bass AJ, Watanabe H, Mermel CH, et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet 2009 Nov; 41 (11): 1238-42
90. Hussenet T, Dali S, Exinger J, et al. SOX2 is an oncogene activated by recurrent 3q26.3 amplifications in human lung squamous cell carcinomas. PLoS One 2010; 5 (1): e8960
91. McCaughan F, Pole JC, Bankier AT, et al. Progressive 3q amplification consistently targets SOX2 in preinvasive squamous lung cancer. Am J Respir Crit Care Med 2010 Jul 1; 182 (1): 83-91
92. Regala RP, Weems C, Jamieson L, et al. Atypical protein kinase C iota is an oncogene in human non-small cell lung cancer. Cancer Res 2005 Oct 1; 65 (19): 8905-11 (Pubitemid 41377380)
93. Chen Y, Shi L, Zhang L, et al. The molecular mechanism governing the oncogenic potential of SOX2 in breast cancer. J Biol Chem 2008 Jun 27; 283 (26): 17969-78
94. Que J, Luo X, Schwartz RJ, et al. Multiple roles for Sox2 in the developing and adult mouse trachea. Development 2009 Jun; 136 (11): 1899-907
95. Wilbertz T, Wagner P, Petersen K, et al. SOX2 gene amplification and protein overexpression are associated with better outcome in squamous cell lung cancer. Mod Pathol 2011 Jul; 24 (7): 944-53
96. Hammerman PS, Sos ML, Ramos AH, et al. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov 2011; 1 (1): 77-87
97. Vogel W, Gish GD, Alves F, et al. The discoidin domain receptor tyrosine kinases are activated by collagen. Mol Cell 1997 Dec; 1 (1): 13-23 (Pubitemid 127376389)
98. Vogel W. Discoidin domain receptors: structural relations and functional implications. FASEB J 1999; 13 Suppl.: S77-82
99. Ikeda K, Wang LH, Torres R, et al. Discoidin domain receptor 2 interacts with Src and Shc following its activation by type I collagen. J Biol Chem 2002 May 24; 277 (21): 19206-12 (Pubitemid 34952488)
100. Olaso E, Labrador JP, Wang L, et al. Discoidin domain receptor 2 regulates fibroblast proliferation and migration through the extracellular matrix in association with transcriptional activation of matrix metalloproteinase-2. J Biol Chem 2002 Feb 1; 277 (5): 3606-13 (Pubitemid 34953233)
101. Haura EB, Tanvetyanon T, Chiappori A, et al. Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. J Clin Oncol 2010 Mar 10; 28 (8): 1387-94
102. Johnson FM, Bekele BN, Feng L, et al. Phase II study of dasatinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 2010 Oct 20; 28 (30): 4609-15
103. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004 Apr 23; 304 (5670): 554 (Pubitemid 38541907)
104. Kawano O, Sasaki H, Endo K, et al. PIK3CA mutation status in Japanese lung cancer patients. Lung Cancer 2006 Nov; 54 (2): 209-15 (Pubitemid 44764916)
105. Carpten JD, Faber AL, Horn C, et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 2007 Jul 26; 448 (7152): 439-44 (Pubitemid 47123510)
106. Malanga D, Scrima M, De Marco C, et al. Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung. Cell Cycle 2008 Mar 1; 7 (5): 665-9 (Pubitemid 351499006)
107. Lord RV, Brabender J, Gandara D, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002 Jul; 8 (7): 2286-91 (Pubitemid 34753602)
108. Cobo M, Isla D, Massuti B, et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 2007 Jul 1; 25 (19): 2747-54 (Pubitemid 47123183)
109. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006 Sep 7; 355 (10): 983-91 (Pubitemid 44343542)
110. Zheng Z, Chen T, Li X, et al. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 2007 Feb 22; 356 (8): 800-8 (Pubitemid 46294612)
111. Lee KH, Min HS, Han SW, et al. ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer. Lung Cancer 2008 Jun; 60 (3): 401-7 (Pubitemid 351726353)
112. Simon GR, Sharma S, Cantor A, et al. ERCC1 expression is a predictor of survival in resected patients with nonsmall cell lung cancer. Chest 2005 Mar; 127 (3): 978-83 (Pubitemid 40775532)
113. Okuda K, Sasaki H, Dumontet C, et al. Expression of excision repair cross-complementation group 1 and class III beta-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer. Lung Cancer 2008 Oct; 62 (1): 105-12
114. Bartolucci R, Wei J, Sanchez JJ, et al. XPG mRNA expression levels modulate prognosis in resected nonsmall-cell lung cancer in conjunction with BRCA1 and ERCC1 expression. Clin Lung Cancer 2009 Jan; 10 (1): 47-52
115. Ceppi P, Volante M, Novello S, et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 2006 Dec; 17 (12): 1818-25 (Pubitemid 44884058)
116. Hwang IG, Ahn MJ, Park BB, et al. ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy. Cancer 2008 Sep 15; 113 (6): 1379-86
117. Reynolds C, Obasaju C, Schell MJ, et al. Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J Clin Oncol 2009 Dec 1; 27 (34): 5808-15
118. Audeh MW, Carmichael J, Penson RT, et al.Oral poly(ADPribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010 Jul 24; 376 (9737): 245-51
119. Quinn JE, James CR, Stewart GE, et al. BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin Cancer Res 2007 Dec 15; 13 (24): 7413-20
120. Fong PC, Yap TA, Boss DS, et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinumfree interval. J Clin Oncol 2010 May 20; 28 (15): 2512-9
121. Bhattacharyya A, Ear US, Koller BH, et al. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 2000 Aug 4; 275 (31): 23899-903 (Pubitemid 30624678)
122. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005 Apr 14; 434 (7035): 917-21 (Pubitemid 40559006)
123. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADPribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009 Jul 9; 361 (2): 123-34
124. Rottenberg S, Jaspers JE, Kersbergen A, et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci USA 2008 Nov 4; 105 (44): 17079-84
125. Tutt A, Robson M, Garber JE, et al. Oral poly(ADPribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010 Jul 24; 376 (9737): 235-44
126. Abbott DW, Thompson ME, Robinson-Benion C, et al. BRCA1 expression restores radiation resistance in BRCA1-defective cancer cells through enhancement of transcription-coupled DNA repair. J Biol Chem 1999 Jun 25; 274 (26): 18808-12
127. Mullan PB, Quinn JE, Gilmore PM, et al. BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents. Oncogene 2001 Sep 27; 20 (43): 6123-31 (Pubitemid 32964424)
128. Taron M, Rosell R, Felip E, et al. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet 2004 Oct 15; 13 (20): 2443-9 (Pubitemid 39377848)
129. Rosell R, Skrzypski M, Jassem E, et al. BRCA1: a novel prognostic factor in resected non-small-cell lung cancer. PLoS One 2007; 2 (11): e1129
130. Rosell R, Perez-Roca L, Sanchez JJ, et al. Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression. PLoS One 2009; 4 (5): e5133
131. Boukovinas I, Papadaki C, Mendez P, et al. Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients. PLoS One 2008; 3 (11): e3695
132. Camps C, Sirera R, Iranzo V, et al. Gene expression and polymorphisms of DNA repair enzymes: cancer susceptibility and response to chemotherapy. Clin Lung Cancer 2007 May; 8 (6): 369-75 (Pubitemid 46924057)
133. Shiraishi K, Kohno T, Tanai C, et al. Association of DNA repair gene polymorphisms with response to platinumbased doublet chemotherapy in patients with non-small-cell lung cancer. J Clin Oncol 2010 Nov 20; 28 (33): 4945-52
134. Thomas RK, Weir B, Meyerson M. Genomic approaches to lung cancer. Clin Cancer Res 2006 Jul 15; 12 (14 Pt 2): 4384-91s
135. Pao W, Kris MG, Iafrate AJ, et al. Integration of molecular profiling into the lung cancer clinic. Clin Cancer Res 2009 Sep 1; 15 (17): 5317-22